CLAIMS

1. Use of a composition comprising allogeneic cytotoxic T cells (CTLs) expressing a T cell receptor that specifically binds to an EBV peptide presented on a class I MHC in the manufacture of a medicament for treating or preventing multiple sclerosis~~an EBV-associated autoimmune disease in a subject~~.

2. The use of claim 1, wherein said CTLs were obtained by selecting from a cell bank allogeneic CTLs expressing a T cell receptor that specifically binds to an EBV peptide presented on a class I MHC.

3. The use of claim 1 or 2, wherein said CTLs were prepared by incubating a sample comprising allogeneic CTLs with antigen-presenting cells (APCs) presenting an EBV peptide, thereby inducing proliferation of peptide-specific CTLs expressing a T cell receptor that specifically binds to an EBV peptide presented on a class I MHC.

4. The use of any one of claims 1 to 3, wherein said CTLs were prepared by :

a) incubating APCs with a nucleic acid construct encoding for an EBV peptide, thereby inducing the APCs to present an EBV peptide; and

b) inducing peptide-specific CTL proliferation by incubating a sample comprising allogeneic CTLs with the EBV peptide-presenting APCs, thereby inducing the proliferation of CTLs expressing a T cell receptor that specifically binds to an EBV peptide presented on a class I MHC.

5. The use of any one of claims 1 to 4, wherein the class I MHC is encoded by an HLA allele that is present in the subject.

6. The use of claim 4 or 5, wherein the nucleic acid construct is a viral vector.

7. The use of claim 6, wherein the viral vector is AdE1-LMPpoly.

8. The use of any one of claims 1 to 7, wherein the allogeneic CTLs are stored in a cell bank before being administered to the subject.

~~9. The use of any one of claims 1 to 8, wherein the EBV-associated autoimmune disease is multiple sclerosis (MS).~~

~~10~~9. The use of any one of claims 1 to ~~9~~8, wherein the multiple sclerosis ~~EBV-associated autoimmune disease~~ is primary progressive MS (PPMS), secondary progressive MS (SPMS), or relapsing remitting MS (RRMS).

~~11. The use of any one of claims 1 to 8, wherein the EBV-associated autoimmune disease is rheumatoid arthritis (RA).~~

~~12~~10. The use of any one of claims 3 to ~~11~~9, wherein the sample comprising CTLs is incubated with one or more cytokines.

~~13~~11. The use of any one of claims 3 to ~~12~~10, wherein the APCs comprise B cells.

~~14~~12. The use of any one of claims 3 to ~~12~~10, wherein the APCs comprise antigen-presenting T-cells.

~~15~~13. The use of any one of claims 3 to ~~12~~10, wherein the APCs comprise dendritic cells.

~~16~~14. The use of any one of claims 3 to ~~12~~10, wherein the APCs comprise artificial antigen-presenting cells.

~~17~~15. The use of claim ~~16~~14, wherein the artificial antigen-presenting cells are aK562 cells.

~~18~~16. The use of any one of claims 3 to ~~17~~15, wherein the sample comprises peripheral blood mononuclear cells (PBMCs).

~~19~~17. The use of any one of claims 1 to ~~18~~16, wherein the EBV peptide comprises a LMP1 peptide ~~or fragment thereof~~.

~~20~~18. The use of any one of claims 1 to ~~18~~16, wherein the EBV peptide comprises a LMP2A peptide ~~or fragment thereof~~.

~~21~~19. The use of any one of claims 1 to ~~18~~16, wherein the EBV peptide comprises an EBNA1 peptide ~~or fragment thereof~~.